The University of California, Berkley’s Professor Richard Kramer – who is experimenting with optogenetics to restore vision – will headline a major meeting at Flinders University focusing on the therapeutic approach that uses light instead of drugs to control specific cells in the body.
The Third Optogenetics Australia meeting on 23-24 February will feature leading scientists in optogenetics and chemogenetics discussing their new methods to control some internal organs. They will share their expertise in understanding how to apply these techniques to various biological systems for treating human illnesses and conditions.
“We are in a renaissance era of neuroscience, thanks to the emergence of new tools and technologies during the past five years,” said Flinders University’s Professor Nick Spencer, who has organised the meeting with colleague Professor Harald Janovjak and Associate Professor Wendy Imlach from Monash University.
“This means that we can now address major unresolved questions to help lives, that we were only once able to dream of. Rather than using conventional drugs to control the body, which almost always have non-specific side effects, scientists attending the meeting will show how they can use light to drive the same processes but with much higher precision.”
Spencer said scientists can now control specific cells and pathways in the body, producing the required light-sensitive proteins inside the body. The meeting will discuss new techniques, tools and applications to target particular organs and improve their outcomes as a therapy.
Each of the experts making presentations at the two-day meeting, being held at the Alere Function Centre at Flinders University’s Bedford Park campus, have different fields of optogenetic expertise.
Spencer said one of the meeting’s highlights will be from US-based Kramer about new strategies for preserving and restoring sight in retinal degeneration.
“Professor Kramer is doing optogenetic experiments in human vision that can restore vision to people who are blind, and his talk comes while he is in Adelaide to observe work at the Royal Adelaide Hospital. His research is at the forefront of translational optogenetic technology,” he said.
“In a further example, with Parkinson’s disease, we know exactly where the problem is and which neurones are deficient, so you can use light to target only those neurones in only that part of the body, rather than taking a medicine, which gets absorbed into the body and can have all sorts of side-effects.”
The list of keynote presenters at the two-day meeting also includes international luminaries in this field including, Chandra Tucker (University of Colorado, USA), Akihiro Yamanaka (Nagoya University, Japan), Alexander Gottschalk (Goethe University, Germany), Gusong Hong (Stanford University, USA), Yves De Koninck (Laval University, Canada) and Ofer Yizhar (Weizmann Institute, Israel).
“The fact Flinders University is hosting this international meeting signals our strength in this field,” Spencer added.
Optogenetics Australia was conceived by Janovjak, an ARC Future Fellow who is the Discipline Lead of Biotechnology at Flinders University.
“This meeting is designed to unify leading researchers in Australia in the field of neurogenetic technologies. This will add more to the collective knowledge among more people about the sum of what advances in optogenetics can achieve,” he said.
The meeting has been sponsored by the Flinders Foundation, Flinders University and the Australasian Neurogastroenterology & Motility Association (ANGMA).
More details about the Optogenetics Australia meeting on 23-24 February at Flinders University, and the program of speakers, can be found here.
More reading
Rewriting eye disease: Are we ready for gene therapies?
Novartis targets GA gene therapy in Gyroscope Therapeutics deal
Sydney surgeon details first Luxturna gene therapy allowing patient to see stars
